Treatment outcomes after adjuvant radiotherapy following surgery for patients with stage i endometrial cancer

Jiyoung Kim, Kyung Ja Lee, Kyung Ran Park, Boram Ha, Yi Jun Kim, Wonguen Jung, Rena Lee, Seung Cheol Kim, Hye Sung Moon, Woong Ju, Yun Hwan Kim, Jihae Lee

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Purpose: The purpose of this study is to evaluate the treatment outcomes of adjuvant radiotherapy using vaginal brachytherapy (VB) with a lower dose per fraction and/or external beam radiotherapy (EBRT) following surgery for patients with stage I endometrial carcinoma. Materials and Methods: The subjects were 43 patients with the International Federation of Gynecology and Obstetrics (FIGO) stage I endometrial cancer who underwent adjuvant radiotherapy following surgery between March 2000 and April 2014. Of these, 25 received postoperative VB alone, while 18 received postoperative EBRT to the whole pelvis; 3 of these were treated with EBRT plus VB. The median EBRT dose was 50.0 Gy (45.0-50.4 Gy) and the VB dose was 24 Gy in 6 fractions. Tumor dose was prescribed at a depth of 5 mm from the cylinder surface and delivered twice per week. Results: The median follow-up period for all patients was 57 months (range, 9 to 188 months). Five-year disease-free survival (DFS) and overall survival (OS) for all patients were 92.5% and 95.3%, respectively. Adjuvant radiotherapy was performed according to risk factors and stage IB, grade 3 and lymphovascular invasion were observed more frequently in the EBRT group. Five-year DFS for EBRT and VB alone were 88.1% and 96.0%, respectively (p = 0.42), and 5-year OS for EBRT and VB alone were 94.4% and 96%, respectively (p = 0.38). There was no locoregional recurrence in any patient. Two patients who received EBRT and 1 patient who received VB alone developed distant metastatic disease. Two patients who received EBRT had severe complications, one each of grade 3 gastrointestinal complication and pelvic bone insufficiency fracture. Conclusion: Adjuvant radiotherapy achieved high DFS and OS with acceptable toxicity in stage I endometrial cancer. VB (with a lower dose per fraction) may be a viable option for selected patients with early-stage endometrial cancer following surgery.

Original languageEnglish
Pages (from-to)265-272
Number of pages8
JournalRadiation Oncology Journal
Issue number4
StatePublished - Dec 2016

Bibliographical note

Publisher Copyright:
© 2016. The Korean Society for Radiation Oncology.


  • Adjuvant radiotherapy
  • Conformal radiotherapy
  • Endometrial cancer
  • Intracavity radiotherapy


Dive into the research topics of 'Treatment outcomes after adjuvant radiotherapy following surgery for patients with stage i endometrial cancer'. Together they form a unique fingerprint.

Cite this